It is the first and only approved fully human, dual-acting monoclonal antibody that blocks IL-23 while also binding to CD64, a receptor on cells that produce IL-23, which is a driver of UC, according to a Sept. 11 press release.
Tremfya is administered as a 200 milligram induction dose intravenously at weeks zero, four and eight by a healthcare professional.
It first received FDA approval in 2017 for the treatment of adult patients with moderate-to-severe plaque psoriasis.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.